CARDOZA GEORGE sold $8K of SOPH

CARDOZA GEORGE (Chief Financial Officer) sold 1,592 shares of SOPHiA GENETICS SA (SOPH) at $5.29 on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CARDOZA GEORGE
Published Jul 7, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
medium confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not include any new guidance, deal, regulatory action, or operational milestone.

02

Market read

Traders may monitor insider activity for sentiment, but the 10b5-1 framing reduces the signal strength.

03

What to watch

Insider sales can be offset by other insider buys or by the fact that the sale size is small relative to typical institutional float; the filing provides no new business information.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-07 after-hours; reflects insider sale executed 2026-07-06.

Background

The article is a primary-source SEC Form 4 insider transaction for SOPHiA GENETICS, reported by its CFO.

Company-level read

Ticker impact

$SOPHNeutralMedium confidence
Context

SOPHiA GENETICS CFO CARDOZA GEORGE filed a Form 4 open-market sale of 1,592 shares at $5.2886 on 2026-07-06.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider activity.

Evidence & confidence

The filing is a routine Form 4 transaction, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying company-specific operational or guidance change.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • SOPHiA GENETICS SA

    Subject of the Form 4 insider transaction; CFO sold shares via an open-market transaction under a 10b5-1 plan.

  • CARDOZA GEORGE

    Chief Financial Officer who reported the sale of 1,592 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September